CompletedPhase 2

IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia

United States7 participantsStarted 2008-01

Plain-language summary

The purpose of this study is to determine the efficacy and safety of rhIL-11, when given subcutaneously for six consecutive months, in reducing menstrual blood loss in women with type 1 von Willebrand disease and refractory menorrhagia. Efficacy will be measured by subjective bleeding severity scale and pictorial bleeding chart. Safety will be measured by the frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Females 18-45 years of age * Confirmed type 1 VWD, as defined by low VWF:RCoF or low VWF:Ag and qualitatively normal VWF multimers * Menorrhagia refractory to estrogens, hormones, hemostatic agents * Willingness to have blood drawn Exclusion Criteria: * Use of immunomodulatory or experimental drugs, or diuretics * Pregnant or lactating women or those unwilling to use contraception during study * Previous cardiac disease, congestive failure, arrhythmia (e.g., atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis * Past allergic reaction to Neumega or DDAVP * Surgery within the past 8 weeks * Inability to comply with study protocol requirements * Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs * Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study

What they're measuring

>50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months

Timeframe: 6 months

Trial details

NCT IDNCT00524342

SponsorMargaret Ragni

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-12

Results submitted2014-06-04